Safety and monitoring
Adverse events, SUSARs, and device effects that name the reporting rules of each authority on the study. Monitoring visit reports, deviations, and a risk indicator scan.
Term, seriousness criteria, expectedness, causality, outcome, and narrative, with versions and follow-ups. Coding is typed by a licensed coder. Every change is audited.
Each serious case names the rules that apply to the study's authorities, such as CTIS 7-day, IND 15-day, or MDR Article 87. People prepare and send the reports.
A case file shaped like E2B(R3) XML can be downloaded for review. It is not a validated E2B transmission and nothing is sent to an authority gateway.
A medical reviewer signs the case review. Safety reconciliation lists cases that need attention.
Emergency unblinding is one participant, one person, and one reason, with a signature. Randomization codes are kept in their own records.
There is no DMC workspace and no endpoint adjudication workflow.
A scan computes risk indicators from the study data and stores the findings. Quality tolerance limits are not set or enforced by the system.
Monitoring visit reports with findings and actions, signed by the monitor. Follow-up letters are written by a person.
Deviations are tracked items with a status and an owner on the study.
Findings are tracked items with an owner and a due date. CAPA effectiveness checks are not a separate workflow.
A person reviews the audit trail for a period and signs the review. The review is stored with its scope and outcome.
We read the study, configure ValidTrials, and the sites work in one record. The first conversation is about your protocol, not a software tour.
Clinical trial management for drugs, devices, and diagnostics. EU and US regulatory packages from one record. CAREPOI CRO, registered with EOF 16 November 2026.
© 2026 CAREPOI · ValidTrials · Helsinki, EU